A widely repeated interaction claim that turns out to be unsupported — what changed since posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Anticoagulant questions come up regularly and are the clearest case for professional advice rather than discussion, because the consequence of being wrong is not gradual.
Confirming post #32 from a second method, which matters more than confirming it from a second person.
Renal or hepatic impairment changes the calculus for a lot of combinations and is the context most often missing from an interaction question here.
I had written a reply contradicting post #30 and deleted it. Here is what survived.
Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an argument for spacing them.
Adding the boring version of widely repeated interaction claim, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Fair, and the limits you put on it are the part I will remember.
Coming back to post #34, because the follow-up matters more than the original answer.
A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is usually worse rather than better.
Narrowing post #36, because the general version has more than one answer.
Anything that also slows gut motility compounds the same mechanism. That is a plausibility argument rather than a documented interaction, and it should be labelled as one.
SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
I would rather say I do not know than round it up to an answer.
Answering the question post #39 raises rather than the one it answers.
Widely repeated interaction claim is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
The arithmetic in post #39 is right; the assumption feeding it is the part to check.
What I want from this widely repeated interaction claim thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Collapsed as off-topic by two members at trust level 3 or above
Separation timing versus clinically important interaction: a separation timing inconvenience (taking one medication 2 hours before or after another) is not the same as a clinically important interaction. Both can reduce absorption of one or the other, but only true interactions require active management.
Worth reading the earlier posts in this thread before acting on mine.
Alcohol is not contraindicated in the labelling and it does irritate a stomach that is already emptying slowly. There is no published interaction study, and the conservative reading is the obvious one.
That is one dataset and I would not build a rule on it.
Everything in post #44 holds. The case it does not cover is the one I have.
Supplements and herbs: many have no established interaction. Some do. If you are taking something unusual, checking a reference (like a pharmacist) is more useful than guessing from forum discussion.
The most defensible general position in this subcategory: identify the plausible mechanism, check whether it has been studied, and where it has not, say that rather than filling the gap.
The confident version of this sentence would be wrong, so here is the hedged one.
The thing about widely repeated interaction claim that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
Building on post #47 rather than restating it.
Nothing here is medical advice and an interaction question is one where the cost of a wrong forum answer is genuinely high. Ask the prescriber or the pharmacist.
Vitamins: most vitamins have no significant interaction. Fat-soluble vitamins (A, D, E, K) might be affected by the slowing of fat absorption during weight loss, but that is a nutritional consequence rather than an interaction.
That is what the documentation says. What happens in practice is usually close.
Anyone asking an interaction question should list everything, including the things they consider irrelevant. The irrelevant one is the answer more often than chance would suggest.
Marking that as an opinion rather than a finding.
Narrowing post #50, because the general version has more than one answer.
Widely repeated interaction claim came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you are on it; monitoring INR more frequently during weight loss is reasonable.
That holds for the case as described. Change the assumptions and it may not.
Research-use-only compounds have no interaction data of any kind, because interaction studies are done on medicines being developed for use in people.
That is the version I use. It may not be the version that is correct.
The arithmetic in post #54 is right; the assumption feeding it is the part to check.
Oral medications with a narrow therapeutic index are the ones where that matters most. The interaction is about rate and timing rather than about the total absorbed, in most published cases.
A pharmacist can answer most questions in this subcategory in a few minutes with access to a proper interaction database, and that access is the thing a forum does not have.
I would be interested in a counterexample if anyone has one.
Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted. That is a reason for close monitoring, not for avoiding the combination.
The honest answer is that it depends, and here is what it depends on.
Post #56 put the caveat in the right place and I want to underline it.
Offering a way to settle widely repeated interaction claim rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
Thank you for taking the time. That was more work than a reply usually is.
Insulin and sulfonylureas are the interaction that the labelling in this class flags most explicitly, because the risk is additive glucose lowering. That is a prescribing question and not a forum question.
Take the reasoning and check the arithmetic; I do not always get it right.